BioStock: NextCell’s CEO comments on long-term potential

NextCell Pharma highlights the positive trends seen in the preliminary ProTrans data in adolescents, while underscoring the need to wait until the end of the trial before drawing statistical conclusions. However, the market has a strong aversion to uncertainty and reacted hard to the one-year results revealed in mid-April. BioStock spoke with CEO Mathias Svahn to gain a deeper understanding of the data.

Read the full article at biostock.se:

https://www.biostock.se/en/2025/04/nextcells-ceo-comments-on-long-term-potential/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se